According to new MODULAR ATP data, the leadless system was associated with a high success rate and few complications. Boston Scientific plans on seeking FDA approval in 2025. 

Complications are also down after SAVR, researchers noted, though the drop has been much more dramatic for TAVR patients. The new analysis was based on Medicare data from more than 210,000 patients.

Should patients stay on beta-blockers more than one year after a heart attack? The team behind the ABYSS clinical trial explored that very question, presenting its data at ESC Congress 2024.

ESC's annual meeting is always one of the world's largest gatherings of cardiologists and other cardiology professionals. This year's 4-day event will be no different. 

The new AUC document was designed to help care teams know when and how to perform imaging-based cardiovascular evaluations on patients undergoing nonemergent, noncardiac surgery.

The Cardiovascular Research Foundation has announced 10 late-breaking clinical trials and 15 late-breaking clinical science sessions for TCT 2024 in Washington, DC. Topics will include TAVR and other structural heart procedures, artificial intelligence and much more. 

Congress is considering two bills that would prevent or mitigate the Medicare physician payment cuts that went into effect in January 2024, and the Society for Cardiovascular Angiography and Interventions is urging members write their Congressmen.

CMS wants feedback after proposing a significant update to CCTA reimbursement payments. The American College of Cardiology, a longtime champion for improved cardiac CT payments, is now helping its members make their voices heard.